Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00999687
Other study ID # CMRPG280191
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date September 2009
Est. completion date September 2010

Study information

Verified date July 2019
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of indigo naturalis oil extract in treating nail psoriasis.


Description:

Nail psoriasis treatment is notoriously difficult. While indigo naturalis has been demonstrated safe and effective in treating skin psoriasis, its effect on nail psoriasis remains unverified.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion criteria:

1. adults aged between 20 and 65 years

2. received a diagnosis of nail psoriasis with at least one year history based on clinical assessment by two dermatologists and failure of topical systemic Chinese herbal anti-psoriasis therapy for fingernail psoriasis.

3. Female patients of childbearing age agreed to continue using birth control measures for the duration of the study.

Exclusion criteria:

1. Patients had non-plaque (i.e., pustular, guttate, or erythrodermic) or drug-induced forms of psoriasis, total body surface involvement of more than 60%

2. a history of allergy to indigo naturalis, or with onychomycosis or any fingernail infection.

3. Patients have received systemic therapy within four weeks before enrollment

4. Patients have received phototherapy within three weeks, or topical psoriasis agents within two weeks.

5. Using medications which affect psoriasis during the study and unwillingness to comply with study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Indigo Naturalis Extract in Oil
Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
Other:
Olive Oil
Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week 12. The nail is divided by imaginary horizontal and longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0-4) and nail matrix psoriasis (0-4) depending on the presence of any of the features of nail psoriasis in that quadrant. The NAPSI score evaluates presence of signs in the nail bed (of onycholysis, splinter hemorrhages, nail bed discoloration, and subungual hyperkeratosis) and on the nail matrix (pitting, leukonychia, red spots in the lunula and nail plate crumbling) in all 10 fingernails, providing a minimal score of 0 and a maximum of 80. This study is an intra-patient side-to-side comparison, it measures nail disease on a single hand. All 5 fingers in each group were scored providing a maximum score of 40 and a minimal of 0. The modified target NAPSI score for the target nail scores severity of nail matrix and nail-bed psoriasis from 0 (no sign) to 3 (severe involvement) in each nail quadrant, providing a maximum score of 96 and a minimal of 0. Baseline and Week 12
Primary Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week 24. The nail is divided by imaginary horizontal and longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0-4) and nail matrix psoriasis (0-4) depending on the presence of any of the features of nail psoriasis in that quadrant. The NAPSI score evaluates presence of signs in the nail bed (of onycholysis, splinter hemorrhages, nail bed discoloration, and subungual hyperkeratosis) and on the nail matrix (pitting, leukonychia, red spots in the lunula and nail plate crumbling) in all 10 fingernails, providing a minimal score of 0 and a maximum of 80. This study is an intra-patient side-to-side comparison, it measures nail disease on a single hand. All 5 fingers in each group were scored providing a maximum score of 40 and a minimal of 0. The modified target NAPSI score for the target nail scores severity of nail matrix and nail-bed psoriasis from 0 (no sign) to 3 (severe involvement) in each nail quadrant, providing a maximum score of 96 and a minimal of 0. Baseline and Week 24
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03209388 - Study of the Efficacy and Safety of Topical P-3073 in the Treatment of Mild to Moderate Psoriatic Fingernail/s Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Completed NCT04580537 - Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails Phase 2
Not yet recruiting NCT03263624 - Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease Phase 4
Completed NCT02606760 - Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis Phase 3
Completed NCT04227288 - A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis Phase 4
Withdrawn NCT03079973 - Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s Phase 3
Completed NCT04380597 - Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Completed NCT03991936 - Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis Phase 4
Recruiting NCT05124080 - An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis Early Phase 1
Completed NCT03757364 - Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis
Completed NCT02168933 - 308nm Excimer Laser for Treatment of Fingernail Psoriasis N/A
Completed NCT02016482 - A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis Phase 3
Completed NCT01445886 - Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis Phase 2/Phase 3
Not yet recruiting NCT05695833 - Nd:YAG Laser and Radiofrequency in Treatment of Fingernail Psoriasis N/A
Completed NCT03616561 - Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)
Completed NCT02235480 - Efficacy and Safety of Tazarotene Gel in Nail Psoriasis Phase 2
Not yet recruiting NCT06150794 - Methotrexate Alone vs Combination With Excimer Light in Nail Psoriasis N/A
Completed NCT03946826 - A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser (PDL) in the Treatment of Nail Psoriasis N/A
Active, not recruiting NCT05072886 - Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis Phase 1